Qyuns Therapeutics Grants Roche Global Exclusive License for QX031N

Reuters

Oct 28

Qyuns <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Grants Roche Global Exclusive License for QX031N

Qyuns Therapeutics Co. Ltd. announced that it has entered into a global exclusive collaboration and license agreement with F. Hoffmann-La Roche Ltd (Roche) for its investigational product QX031N. Under the terms of the agreement, Qyuns Therapeutics will grant Roche the exclusive global rights to develop, manufacture, and commercialize QX031N. The company will receive a one-time, non-refundable upfront payment of US$75 million and is eligible to receive up to US$995 million in milestone payments related to development, regulatory approval, and commercialization of the product, as well as tiered royalties on potential future sales. QX031N is a long-acting bispecific antibody intended for the treatment of respiratory diseases such as COPD and asthma. The agreement is subject to customary closing conditions, including regulatory approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qyuns Therapeutics Co. Ltd. published the original content used to generate this news brief on October 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2578621931"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578621931\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578621931?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 17:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578621931","market":"nz","top_or_hot":-1,"title":"Qyuns Therapeutics Grants Roche Global Exclusive License for QX031N","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Qyuns <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Grants Roche Global Exclusive License for QX031N\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Qyuns Therapeutics Co. Ltd. announced that it has entered into a global exclusive collaboration and license agreement with F. Hoffmann-La Roche Ltd (Roche) for its investigational product QX031N. Under the terms of the agreement, Qyuns Therapeutics will grant Roche the exclusive global rights to develop, manufacture, and commercialize QX031N. The company will receive a one-time, non-refundable upfront payment of US$75 million and is eligible to receive up to US$995 million in milestone payments related to development, regulatory approval, and commercialization of the product, as well as tiered royalties on potential future sales. QX031N is a long-acting bispecific antibody intended for the treatment of respiratory diseases such as COPD and asthma. The agreement is subject to customary closing conditions, including regulatory approvals.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qyuns Therapeutics Co. Ltd. published the original content used to generate this news brief on October 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qyuns Therapeutics Grants Roche Global Exclusive License for QX031N</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQyuns Therapeutics Grants Roche Global Exclusive License for QX031N\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-28 17:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Qyuns <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Grants Roche Global Exclusive License for QX031N\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Qyuns Therapeutics Co. Ltd. announced that it has entered into a global exclusive collaboration and license agreement with F. Hoffmann-La Roche Ltd (Roche) for its investigational product QX031N. Under the terms of the agreement, Qyuns Therapeutics will grant Roche the exclusive global rights to develop, manufacture, and commercialize QX031N. The company will receive a one-time, non-refundable upfront payment of US$75 million and is eligible to receive up to US$995 million in milestone payments related to development, regulatory approval, and commercialization of the product, as well as tiered royalties on potential future sales. QX031N is a long-acting bispecific antibody intended for the treatment of respiratory diseases such as COPD and asthma. The agreement is subject to customary closing conditions, including regulatory approvals.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qyuns Therapeutics Co. Ltd. published the original content used to generate this news brief on October 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDL36m36x:1","article_id":"2578621931","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578621931","pubTimestamp":1761645364,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Qyuns Therapeutics Co. Ltd. announced that it has entered into a global exclusive collaboration and license agreement with F. Hoffmann-La Roche Ltd  for its investigational product QX031N. Under the terms of the agreement, Qyuns Therapeutics will grant Roche the exclusive global rights to develop, manufacture, and commercialize QX031N. The company will receive a one-time, non-refundable upfront payment of US$75 million and is eligible to receive up to US$995 million in milestone payments related to development, regulatory approval, and commercialization of the product, as well as tiered royalties on potential future sales. QX031N is a long-acting bispecific antibody intended for the treatment of respiratory diseases such as COPD and asthma. The agreement is subject to customary closing conditions, including regulatory approvals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely info","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02509":"荃信生物-B"},"translate_title":"Qyuns Therapeutics授予罗氏QX031N全球独家许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":0.9},"content_text":"Qyuns Therapeutics Grants Roche Global Exclusive License for QX031N\n    \n\n        Qyuns Therapeutics Co. Ltd. announced that it has entered into a global exclusive collaboration and license agreement with F. Hoffmann-La Roche Ltd (Roche) for its investigational product QX031N. Under the terms of the agreement, Qyuns Therapeutics will grant Roche the exclusive global rights to develop, manufacture, and commercialize QX031N. The company will receive a one-time, non-refundable upfront payment of US$75 million and is eligible to receive up to US$995 million in milestone payments related to development, regulatory approval, and commercialization of the product, as well as tiered royalties on potential future sales. QX031N is a long-acting bispecific antibody intended for the treatment of respiratory diseases such as COPD and asthma. The agreement is subject to customary closing conditions, including regulatory approvals.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qyuns Therapeutics Co. Ltd. published the original content used to generate this news brief on October 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}